BACKGROUND: Alterations in hedgehog signaling are implicated in the pathogenesis of basal-cell carcinoma. Although most basal-cell carcinomas are treated surgically, no effective therapy exists for locally advanced or metastatic basal-cell carcinoma. A phase 1 study of vismodegib (GDC-0449), a first-in-class, small-molecule inhibitor of the hedgehog pathway, showed a 58% response rate among patients with advanced basal-cell carcinoma. METHODS: In this multicenter, international, two-cohort, nonrandomized study, we enrolled patients with metastatic basal-cell carcinoma and those with locally advanced basal-cell carcinoma who had inoperable disease or for whom surgery was inappropriate (because of multiple recurrences and a low likelihood of surgical cure, or substantial anticipated disfigurement). All patients received 150 mg of oral vismodegib daily. The primary end point was the independently assessed objective response rate; the primary hypotheses were that the response rate would be greater than 20% for patients with locally advanced basal-cell carcinoma and greater than 10% for those with metastatic basal-cell carcinoma. RESULTS: In 33 patients with metastatic basal-cell carcinoma, the independently assessed response rate was 30% (95% confidence interval [CI], 16 to 48; P=0.001). In 63 patients with locally advanced basal-cell carcinoma, the independently assessed response rate was 43% (95% CI, 31 to 56; P<0.001), with complete responses in 13 patients (21%). The median duration of response was 7.6 months in both cohorts. Adverse events occurring in more than 30% of patients were muscle spasms, alopecia, dysgeusia (taste disturbance), weight loss, and fatigue. Serious adverse events were reported in 25% of patients; seven deaths due to adverse events were noted. CONCLUSIONS: Vismodegib is associated with tumor responses in patients with locally advanced or metastatic basal-cell carcinoma. (Funded by Genentech; Erivance BCC ClinicalTrials.gov number, NCT00833417.).
BACKGROUND: Alterations in hedgehog signaling are implicated in the pathogenesis of basal-cell carcinoma. Although most basal-cell carcinomas are treated surgically, no effective therapy exists for locally advanced or metastatic basal-cell carcinoma. A phase 1 study of vismodegib (GDC-0449), a first-in-class, small-molecule inhibitor of the hedgehog pathway, showed a 58% response rate among patients with advanced basal-cell carcinoma. METHODS: In this multicenter, international, two-cohort, nonrandomized study, we enrolled patients with metastatic basal-cell carcinoma and those with locally advanced basal-cell carcinoma who had inoperable disease or for whom surgery was inappropriate (because of multiple recurrences and a low likelihood of surgical cure, or substantial anticipated disfigurement). All patients received 150 mg of oral vismodegib daily. The primary end point was the independently assessed objective response rate; the primary hypotheses were that the response rate would be greater than 20% for patients with locally advanced basal-cell carcinoma and greater than 10% for those with metastatic basal-cell carcinoma. RESULTS: In 33 patients with metastatic basal-cell carcinoma, the independently assessed response rate was 30% (95% confidence interval [CI], 16 to 48; P=0.001). In 63 patients with locally advanced basal-cell carcinoma, the independently assessed response rate was 43% (95% CI, 31 to 56; P<0.001), with complete responses in 13 patients (21%). The median duration of response was 7.6 months in both cohorts. Adverse events occurring in more than 30% of patients were muscle spasms, alopecia, dysgeusia (taste disturbance), weight loss, and fatigue. Serious adverse events were reported in 25% of patients; seven deaths due to adverse events were noted. CONCLUSIONS: Vismodegib is associated with tumor responses in patients with locally advanced or metastatic basal-cell carcinoma. (Funded by Genentech; Erivance BCC ClinicalTrials.gov number, NCT00833417.).
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: M R Gailani; M Ståhle-Bäckdahl; D J Leffell; M Glynn; P G Zaphiropoulos; C Pressman; A B Undén; M Dean; D E Brash; A E Bale; R Toftgård Journal: Nat Genet Date: 1996-09 Impact factor: 38.330
Authors: Hong-Xiang Liu; Donald K Maccallum; Chris Edwards; William Gaffield; Charlotte M Mistretta Journal: Dev Biol Date: 2004-12-15 Impact factor: 3.582
Authors: Richard A Graham; Bert L Lum; Sravanthi Cheeti; Jin Yan Jin; Karin Jorga; Daniel D Von Hoff; Charles M Rudin; Josina C Reddy; Jennifer A Low; Patricia M Lorusso Journal: Clin Cancer Res Date: 2011-02-07 Impact factor: 12.531
Authors: Patricia M LoRusso; Charles M Rudin; Josina C Reddy; Raoul Tibes; Glen J Weiss; Mitesh J Borad; Christine L Hann; Julie R Brahmer; Ilsung Chang; Walter C Darbonne; Richard A Graham; Kenn L Zerivitz; Jennifer A Low; Daniel D Von Hoff Journal: Clin Cancer Res Date: 2011-02-07 Impact factor: 12.531
Authors: J M Bonifas; S Pennypacker; P T Chuang; A P McMahon; M Williams; A Rosenthal; F J De Sauvage; E H Epstein Journal: J Invest Dermatol Date: 2001-05 Impact factor: 8.551
Authors: M Aszterbaum; A Rothman; R L Johnson; M Fisher; J Xie; J M Bonifas; X Zhang; M P Scott; E H Epstein Journal: J Invest Dermatol Date: 1998-06 Impact factor: 8.551
Authors: C Chiang; R Z Swan; M Grachtchouk; M Bolinger; Y Litingtung; E K Robertson; M K Cooper; W Gaffield; H Westphal; P A Beachy; A A Dlugosz Journal: Dev Biol Date: 1999-01-01 Impact factor: 3.582
Authors: Daniel D Von Hoff; Patricia M LoRusso; Charles M Rudin; Josina C Reddy; Robert L Yauch; Raoul Tibes; Glen J Weiss; Mitesh J Borad; Christine L Hann; Julie R Brahmer; Howard M Mackey; Bertram L Lum; Walter C Darbonne; James C Marsters; Frederic J de Sauvage; Jennifer A Low Journal: N Engl J Med Date: 2009-09-02 Impact factor: 91.245
Authors: Archana Kumari; Alexandre N Ermilov; Benjamin L Allen; Robert M Bradley; Andrzej A Dlugosz; Charlotte M Mistretta Journal: J Neurophysiol Date: 2014-11-12 Impact factor: 2.714
Authors: Markus Eberl; Doris Mangelberger; Jacob B Swanson; Monique E Verhaegen; Paul W Harms; Marcus L Frohm; Andrzej A Dlugosz; Sunny Y Wong Journal: Cancer Cell Date: 2018-01-27 Impact factor: 31.743
Authors: V Kakkassery; K U Loeffler; M Sand; K R Koch; A M Lentzsch; A C Nick; I A Adamietz; L M Heindl Journal: Ophthalmologe Date: 2017-03 Impact factor: 1.059